Zydus challenges ruling in Takeda antitrust dispute

Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Endo sues Indian drug maker over anti-smoking drug patent

10 August 2023 Patent-in-suit relates to a synthetic drug used to treat nicotine dependence | Development comes after USFood and Drug Administration sets new guidelines forcing the withdrawal of another big pharma firm’s rival drug.

Americas

Third Circuit backs pharma firm in antitrust clash

13 December 2022 Years-long dispute centred on treatment for gastroesophageal reflux disease | Case invited questions concerning Noerr-Pennington doctrine and immunity | Takeda | Zydus.

Americas

Supernus hits Zydus with repeat suit over migraine drug

20 September 2021 Supernus Pharmaceuticals has once again accused Indian generic drugmaker Zydus Cadila and its US unit of allegedly infringing 10 patents with its copycat of Trokendi XR (topiramate), a drug for migraines and seizures.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Zydus challenges ruling in Takeda antitrust dispute

More on this story

Editor's picks

Editor's picks

More features